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1. Introduction 28	  
The future of medicine design and manufacture is likely to move away from mass production 29	  
of tablets/capsules of limited dose range towards extemporaneous fabrication of unit dosage 30	  
forms of any dose, personalised to the patient. The factors driving this change include the 31	  
development of low dose drugs with narrow therapeutic indices (for instance 32	  
immunosuppressants and/or blood thinners), the increasing awareness and importance of 33	  
pharmacogenomics (for instance in the drug sensitivity of cancer sufferers, Kim et al, 2012) 34	  
and the need to formulate drug combinations. To face this challenge, the pharmaceutical 35	  
industry needs to evaluate and embrace novel manufacturing technologies. One technology 36	  
with such potential is 3D printing (3DP).  37	  
 38	  
Of the many types of 3D printer commercially available, fused-deposition modelling (FDM) 39	  
offers perhaps the most immediate potential to unit dose fabrication. In FDM 3DP an 40	  
extruded polymer filament is passed through a heated tip. The heat softens the polymer and 41	  
it is then deposited on a build plate. The temperature of the build plate can be controlled and 42	  
is set so that the polymer hardens. The print head deposits polymer on the build plate in the 43	  
x-y dimensions, creating one layer of the object to be printed. The build plate then lowers 44	  
and the next layer is deposited. In this fashion, an object can be fabricated in three 45	  
dimensions, and in a matter of minutes. The particular benefit of FDM 3DP to pharmaceutics 46	  
is that the polymer filament can be loaded with a drug prior to printing, and so drug-loaded 47	  
unit dosage forms can be manufactured. This principle has been demonstrated, for example, 48	  
to tablets containing fluorescein (Goyanes et al, 2014), 4-aminosalicylate and 5-49	  
aminosalicylate (Goyanes et al, 2015) and (Skowyra et al, 2015). 50	  
 51	  
A further potential benefit of FDM 3DP, currently unexplored, is that the printer can be used 52	  
to fabricate tablets of any geometry, including shapes that would be impossible to create by 53	  
powder compaction. Since in principle the shape of a tablet could control its dissolution 54	  
profile, FDM 3DP would seem to offer a new route to design controlled-release or modified-55	  
release dosage forms. The aim of this work, therefore, was to print tablets in a diverse range 56	  
of geometries, many not attainable by powder compaction, and to correlate their geometric 57	  
parameters with dissolution behaviour.  58	  
 59	  
2. Materials and methods 60	  
Polyvinyl alcohol (PVA, a water-soluble synthetic polymer of molecular formula (C2H4O)n) 61	  
was purchased as an extruded filament (1.75mm diameter, print temperature 190-220°C, 62	  
batch No: 2013-10-18, Makerbot Inc., USA). Paracetamol USP grade was obtained from 63	  
(Sigma-Aldrich, UK). Salts for preparing buffer dissolution media were purchased from VWR 64	  
International Ltd., Poole, UK. 65	  
 66	  
2.1 Preparation of PVA filament loaded with drug 67	  
The commercial PVA filament (38g) was cut into small pieces (~1 mm) using a Pharma 11 68	  
Varicut Pelletizer (Thermo Fisher Scientific, UK) and mixed with paracetamol (2g, 5% drug 69	  
w/w) for 10 minutes in a Turbula® T2F shaker-mixer (Glen Mills Inc., USA). The mixture was 70	  
extruded using a single-screw FilaBot® hot melt extruder (Filabot, USA) at 180 °C through a 71	  
1.75 mm diameter nozzle (screw speed 35 rpm). The extruded filaments obtained were 72	  
protected from light and kept in a vacuum desiccator until printing. The drug-loading of the 73	  
filaments was determined by HPLC analysis. 74	  
 75	  
2.2. Printing of paracetamol dosage forms 76	  
Tablets were fabricated with the drug-loaded filaments using a standard fused-deposition 77	  
modelling 3D printer, MakerBot Replicator 2X Desktop 3D printer (MakerBot Inc, USA). The 78	  
templates used to print the tablets were designed with AutoCAD 2014® (Autodesk Inc., USA) 79	  
and exported as a stereolithography (.stl) file into MakerWare v. 2.4.1 (MakerBot Inc., USA). 80	  
The .stl format encodes only the surface data of the object to be printed and requires the 81	  
thickness of the surface to be defined in order to print the desired object. The printer settings 82	  
were as follows: standard resolution with the raft option deactivated and an extrusion 83	  
temperature of 180 °C, speed while extruding (90mm/s), speed while traveling (150mm/s), 84	  
number of shells (2) and layer height (0.20mm). The infill percentage was 100% in order to 85	  
produce tablets of high density.The selected 3D geometries were cube, pyramid, cylinder, 86	  
sphere and torus (Figure 1). The sizes of the shapes were varied using the scale function of 87	  
the software to fabricate tablets of constant surface area (275 mm2), surface area/volume 88	  
ratio (1:1) or weight (500 mg), Tables 1-3. In all cases, however, the ratio of the length, width 89	  
and height of each shape was kept constant.  90	  
 91	  
2.3 Scanning electron microscopy (SEM)  92	  
Surface and cross-section images of the filaments were taken with an SEM (JSM-840A 93	  
Scanning Microscope, JEOL GmbH, Eching, Germany). All samples for SEM testing were 94	  
coated with carbon (∼30–40 nm). 95	  
 96	  
2.4 Thermal analysis 97	  
Filaments were characterised with differential scanning calorimetry (DSC) and 98	  
thermogravimetric analysis (TGA). DSC measurements were performed with a Q2000 DSC 99	  
(TA instruments, Waters, LLC, USA) at a heating rate of 10°C/min. Calibration for cell 100	  
constant and enthalpy was performed with indium (Tm = 156.6°C, ∆Hf =28.71 J/g) according 101	  
to the manufacturer instructions. Nitrogen was used as a purge gas with a flow rate of 50 102	  
mL/min for all the experiments. Data were collected with TA Advantage software for Q series 103	  
(version 2.8.394), and analysed using TA Instruments Universal analysis 2000. All melting 104	  
temperatures are reported as extrapolated onset unless otherwise stated. TA aluminium 105	  
pans and lids (Tzero) were used with an average sample mass of 8-10mg.  106	  
 107	  
For TGA analysis, samples were heated at 10°C/min in open aluminium pans with a 108	  
Discovery TGA (TA instruments, Waters, LLC, USA). Nitrogen was used as a purge gas with 109	  
a flow rate of 25 mL/min. Data collection and analysis were performed using TA Instruments 110	  
Trios software and % mass loss and/or onset temperature were calculated. 111	  
2.5 Characterisation of tablet morphology  112	  
The physical dimensions of the tablets were measured using a digital calliper. Pictures of the 113	  
tablets were taken with a Nikon CoolpixS6150 with the macro option of the menu. The 114	  
surface areas and volumes of the tablets were calculated based on these dimensions. The 115	  
surface area to volume ratio was obtained dividing these values. 116	  
 117	  
2.6 Determination of drug loading  118	  
A tablet or a section of drug-loaded strand (approx. 0.3g) was placed in a volumetric flask 119	  
with deionized water (1L) with magnetic stirring until complete dissolution. Samples of 120	  
solution were then filtered through 0.45 µm filters (Millipore Ltd, Ireland) and the 121	  
concentration of drug determined with HPLC (Hewlett Packard 1050 Series HPLC system, 122	  
Agilent Technologies, UK). The validated high performance liquid chromatographic assay 123	  
entailed injecting 20 µL samples for analysis using a mobile phase, consisting of methanol 124	  
(15%) and water (85%), through a Luna 5µm C8 column, 25 x 4.6 cm (Phenomenex, UK) 125	  
maintained at 40 °C. The mobile phase was pumped at a flow rate of 1 mL/min and the 126	  
eluent was screened at a wavelength of 247 nm. All measurements were made in duplicate.  127	  
 128	  
2.7 Dissolution testing 129	  
Dissolution profiles were obtained using a USP-II apparatus (Model PTWS, Pharmatest, 130	  
Germany). In each assay, the tablets were placed at the bottom of the vessel in phosphate 131	  
buffer (pH= 6.8, 900 mL) under constant paddle stirring (50 rpm) at 37°C. During the 132	  
dissolution test, samples of paracetamol were automatically removed and filtered through 133	  
10µm filters and drug concentration was determined using an in-line UV spectrophotometer 134	  
(Cecil 2020, Cecil Instruments Ltd., Cambridge, UK) operated at the wavelength of 135	  
maximum absorbance of the drug in phosphate buffer (243 nm). Data were processed using 136	  
Icalis software (Icalis Data Systems Ltd, Berkshire, UK). Tests were conducted in triplicate 137	  
under sink conditions. 138	  
 139	  
3. Results and discussion 140	  
The first important result was that it was possible to fabricate all of the shapes with 3DP, 141	  
Figure 2. Manufacture of such complex and intricate shapes by powder compaction would 142	  
be extremely challenging and so the study immediately suggests that 3DP offers a route of 143	  
manufacture of dosage forms of novel geometries not previously possible. As found in our 144	  
previous studies (Goyanes et al, 2014, 2015), 3DP tablets were not friable and so easy to 145	  
handle. 146	  
 147	  
DSC and TGA analyses of the pure substances and extruded filament were performed in 148	  
order to understand how the drug was incorporated in the polymer, Figures 3-5. It is 149	  
apparent that paracetamol raw material melts around 168 oC, indicative of form I while PVA 150	  
shows a glass transition around 135 oC and melting between 175-200 oC. Significant 151	  
degradation of PVA is seen above 260 oC, but the printhead temperature used during tablet 152	  
fabrication is 230 oC. The DSC data of the paracetamol-loaded PVA filament shows no 153	  
evidence of melting around 168 oC, indicating that the drug is molecularly dispersed within 154	  
the polymer matrix as a solid solution. A glass transition is seen in both experiments 155	  
involving PVA (highlighted by the arrows in Figure 4), the temperature of which rises when 156	  
paracetamol is present, suggesting the drug is acting as an anti-plasticiser. TGA data 157	  
suggests that PVA is stable until 260 oC, consistent with the DSC data, while paracetamol 158	  
degrades significantly above 200 oC. When paracetamol is incorporated into the PVA, no 159	  
appreciable mass loss is seen, suggesting the polymer is stabilising the drug. 160	  
 161	  
Percentage drug loadings were measured for the filament (3.95% ± 0.01) and printed tablets 162	  
(3.78% ± 0.01), indicating little degradation of the drug during printing, consistent with the 163	  
thermal stability of paracetamol above its melting point seen by DSC. Electron micrographs 164	  
show little evidence of paracetamol crystallites within the polymer filaments, Figure 7, 165	  
consistent with the DSC data. Images of the cross-section of the printed torus clearly show 166	  
the individual strands deposited by the printer. The strands are ca. 100 µm in diameter, 167	  
consistent with the nozzle diameter of the printhead, and there is some evidence of fusion of 168	  
strands, leading to the strength of the tablet noted earlier. 169	  
 170	  
Dissolution tests reveal that the geometry plays an important role in defining drug release 171	  
profiles, Figure 7. When the surface area of the tablets was kept constant, drug release rates 172	  
were in the following order (fastest first); pyramid > torus > cube > sphere and cylinder. The 173	  
time to 90% release (t90) varied from just under 2h (pyramid) to nearly 12 h (sphere and 174	  
cylinder). When tablets were prepared with a constant surface area/volume ratio, the order 175	  
of release rates was (fastest first); sphere and cube > torus  > cylinder > pyramid. Less 176	  
differentiation was seen in the t90 values, with most shapes having a value between 2-3h. 177	  
Only the pyramid gave noticeably slower release (9 h). Interestingly, when tablets were 178	  
prepared to constant weight, dissolution behavior was similar for all geometries. Since PVA 179	  
releases drug via erosion, it seems that the controlling factor is simply the mass of polymer 180	  
present. The data do show, however, that it is possible to design a tablet with a controlled-181	  
release profile (varying over 10h) by careful selection of shape and/or size. 182	  
 183	  
  184	  
 185	  
 186	  
Shape Surface area (mm2) 
Volume 
(mm3) 
SA/V ratio Weight (mg) 
Density 
(mg/mm3) 
Cube 287.9 ± 2.1 332.3 ± 3.6 0.866 ± 0.003 268.2 ± 15.7 0.81 ± 0.05 
Pyramid 270.4 ± 0.4 231.3 ± 0.5 1.169 ± 0.001 187.5 ± 3.9 0.81 ± 0.02 
Cylinder 268.5 ± 3.9 314.4 ± 6.5 0.854 ± 0.005 355.3 ± 23.7.5 1.13 ± 0.05 
Sphere 280.8 ± 1.4 442.3 ± 3.2 0.634 ± 0.002 505.3 ± 36.0 1.14 ± 0.08 
Torus 266.8 ± 1.0 266.4 ± 1.9 1.002 ± 0.004 276.0 ± 19.6 1.04 ± 0.08 
 187	  
Table 1: Physical parameters for tablets with similar surface areas 188	  
  189	  
 190	  
Shape 
Surface area 
(mm2) 
Volume 
(mm3) 
SA/V ratio  Weight (mg)  
Density 
(mg/mm3)  
Cube 212.1 ± 2.2 210.1 ± 3.3 1.009 ± 0.005 186.9 ± 19.3 0.89 ± 0.11 
Pyramid 356.1 ± 2.7 353.7 ± 5.2 1.007 ± 0.008 451.2 ± 12.0 1.28 ± 0.05 
Cylinder 200.8 ± 3.2 202.3 ± 4.0 0.992 ± 0.004 197.6 ± 4.0 0.97 ± 0.18 
Sphere 111.5 ± 1.2 110.7 ± 1.9 1.007 ± 0.006 98.5 ± 0.9 0.89 ± 0.05 
Torus 266.8 ± 1.0 266.4 ± 1.9 1.002 ± 0.004 276.0 ± 19.6 1.04 ± 0.08 
 191	  
Table 2: Physical parameters for tablets with similar surface/volume ratios 192	  
 193	  
  194	  
 195	  
Shape 
Surface area 
(mm2) 
Volume 
(mm3) 
SA/V ratio Weight (mg) 
Density 
(mg/mm3) 
Cube 341.4 ± 0.5 429.2 ± 1.0 0.795 ± 0.001 477.9 ± 11.9 1.11 ± 0.03 
Pyramid 393.0 ± 15.2 406.2 ± 23.4 0.968 ± 0.019 494.8 ± 16.6 1.22 ± 0.03 
Cylinder 335.0 ± 15.7 438.3 ± 29.3 0.765 ± 0.016 480.0 ± 11.0 1.10 ± 0.06 
Sphere 280.8 ± 1.4 442.3 ± 3.2 0.634 ± 0.002 505.3 ± 36.0 1.14 ± 0.08 
Torus 387.0 ± 3.0 479.5 ± 4.3 0.807 ± 0.001 509.9 ± 29.0 1.06 ± 0.05 
 196	  
Table 3: Physical parameters for tablets with similar weights 197	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 200	  
 201	  
 202	  
 203	  
 204	  
 205	  
 206	  
 207	  
 208	  
 209	  
 210	  
 211	  
  212	  
 213	  
 214	  
Figure 1. 3D representation of the 3D geometries printed (left to right; cube, pyramid, 215	  
cylinder, sphere and torus) 216	  
 217	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Figure 2: Images of the 3DP fabricated tablets at constant (A) Surface area, (B) surface 231	  
area/volume ratio and (C) mass. 232	  
 233	  
  234	  
A	  
B	  
C	  
 235	  
 236	  
Figure 3. DSC thermal trace for paracetamol raw material, showing melt of the stable form I 237	  
at 168 oC. 238	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Figure 4. DSC thermal traces for PVA and PVA-paracetamol filaments. The PVA melts 243	  
between 175-200 oC and the arrows indicate glass transition temperatures. 244	  
 245	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Figure 5. TGA thermal traces for paracetamol raw material and PVA and PVA-paracetamol 249	  
filaments. 250	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Figure 6. SEM images of the surface and cross-section of; Top) PVA filament, middle) PVA-254	  
paracetamol filament and bottom) a section of printed filament (in this case from the torus). 255	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Figure 7: Paracetamol dissolution profiles from 3DP solid dosage with A) surface area 275 259	  
mm2, B) surface area/volume ratio 1 and C) 500 mg mass in phosphate buffer (pH 6.8) 260	  
Conclusions 261	  
 262	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